Products and Services - MACS Cell Culture and Stimulation - TLR Ligands - TLR9 Agonists

TLR9 Agonists – Effective activation of pDCs and B cells

  • Synthetic oligonucleotides containing CpG motifs (CpG ODNs)
  • Potent and specific immune cell stimulation in human and mouse
  • Ultra-pure, endotoxin-free
  • Easy handling, with buffers included
Toll-like receptors (TLRs) recognize highly conserved structural motifs as a part of the early innate immune response to invading pathogens. TLR9 is critical to distinguishing microbial from mammalian DNA, leading to the activation of immune cells.

Synthetic oligonucleotides containing CpG motifs (CpG ODNs) mimic the immune stimulatory effect of bacterial DNA, promoting Th1 and pro-inflammatory cytokines induction which facilitates maturation / activation of antigen-presenting cells.

We provide quality Toll-like receptor 9 (TLR9) agonists for activating immune cells and their respective controls, with dedicated support from our experts in DC and B cell research. Don’t settle for less.

Four classes of TLR9 Agonists have been identified which differ in their effects on cells.

A-Class: induce high levels of type I IFN but show low activation of B cell proliferation. They are useful for pDC activation and IFN-α induction from human PBMC and activation of IFN-signaling pathways. A-Class ODNs contain 5' and 3' G-rich stretches and can form tertiary structures (G-tetrads).

B-Class: activate B cells and TLR9-dependent NF-κB signaling in recombinant cell lines but show low induction of IFN-α. They are utilized in B cell activation and IL-6 induction from human PBMC and activation of NF-κB signaling pathways.

C-Class: combine features of both types A and B. They strongly induce IFN-α production by pDCs as well as B cell stimulation. C-Class ODN form dimeric structures.

P-Class: activate both pDCs and B cells with higher efficiency than C-Class agonists. They can form multimeric structures.

Overview of the specific efficiencies of the four ODN classes

Comparison of ODN classes and concentrations with respect to IL-6 induction. Human PBMCs were incubated for 24 hours with the indicated amounts of ODNs. Read-out was performed by ELISA assay.

Comparison of ODN classes and concentrations with respect to IFN-α induction. Human PBMCs were incubated for 24 hours with the indicated amounts of ODNs. Read-out was performed by ELISA.

Percentage of B cell activation with respect to ODN classes and concentrations. Human PBMCs were incubated with ODNs in the indicated amounts for 48 hours and stained for CD19, CD80, and CD86, then analyzed by flow cytometry gated on viable CD19+ B cells.

Proliferation of B cells with respect to ODN classes and concentrations. PBMC were stained with carboxyfluorescein diacetate succinimidyl ester, incubated with ODN and cultured for 6 days. Cells were stained with CD19 mAb and analyzed with the MACSQuant® Analyzer. Cells were gated on live CD19+ cells and % proliferating B cells were measured by decrease in CFSE content.

A-Class agonists induce high levels of type I IFN but show low activation of B cell proliferation. They are useful for pDC activation and IFN-α induction from human PBMC and activation of IFN-signaling pathways. A-Class ODNs contain 5' and 3' G-rich stretches and can form tertiary structures (G tetrads).

IFN-α production in PBMCs with respect to ODN concentration. Human PBMCs were incubated for 24 hours with the indicated amounts of ODN. Read-out was performed by ELISA.

IL-6 production in PBMCs with respect to ODN concentration. Human PBMCs were incubated for 24 hours with the indicated amounts of ODN. Read-out was performed by ELISA.

TLR9-mediated NF-κB activation in a recombinant cell line. HEK293 cells were stably transfected with a TLR9-expression plasmid and an NF-κB-luciferase reporter plasmid. Cells were incubated for 16 hours with CpG ODN. TLR9-mediated NF-κB activity was detected by measuring luciferase activity by chemiluminescence. n-fold activation of luciferase expression was calculated in reference to medium background activity (no ODN added).

Proliferation of B cells with respect to ODN concentration. Human PBMCs were stained with carboxyfluorescein diacetate succinimidyl ester, incubated with ODN and cultured for 6 days. Cells were stained with CD19 mAb and analyzed with the MACSQuant® Analyzer. Cells were gated on live CD19+ cells and % proliferating B cells were measured by decrease in CFSE content.

B cell activation with respect to ODN concentration. Human PBMCs were incubated with ODNs in the indicated amounts for 48 hours and stained for CD19, CD80, and CD86, then analyzed by flow cytometry using the MACSQuant® Analyzer. Cells were gated on live CD19+ cells.

B-Class agonists activate B cells and TLR9-dependent NF-κB signaling in recombinant cell lines but show low induction of IFN-α. They are utilized in B cell activation and IL-6 induction from human PBMC and activation of NF-κB signaling pathways.

IL-6 production in PBMCs with respect to ODN concentration. Human PBMCs were incubated for 24 hours with the indicated amounts of ODNs. Read-out was performed by ELISA.

TLR9-mediated NF-κB activation in a recombinant cell line. HEK293 cells were stably transfected with a TLR9-expression plasmid and an NF-κB-luciferase reporter plasmid. Cells were incubated for 16 hours with CpG ODN. TLR9-mediated NF-κB activity was detected by measuring luciferase activity by chemiluminescence. n-fold activation of luciferase expression was calculated in reference to medium background activity (no ODN added).

B cell activation with respect to ODN concentration. Human PBMCs were incubated with ODNs in the indicated amounts for 48 hours and stained for CD19, CD80, and CD86, then analyzed by flow cytometry using the MACSQuant® Analyzer. Cells were gated on live CD19+ cells.

Proliferation of B cells with respect to ODN concentration. Human PBMCs were stained with carboxyfluorescein diacetate succinimidyl ester, incubated with ODN and cultured for 6 days. Cells were stained with CD19 mAb and analyzed with the MACSQuant® Analyzer. Cells were gated on live CD19+ cells and % proliferating B cells were measured by decrease in CFSE content.

C-Class: combine features of both types A and B. They strongly induce IFN-α production by pDCs as well as B cell stimulation. C-Class ODN form dimeric structures.

IFN-α production in PBMCs with respect to ODN concentration. Human PBMCs were incubated for 24 hours with the indicated amounts of ODNs. Read-out was performed by ELISA.

IL-6 production in PBMCs with respect to ODN concentration. Human PBMCs were incubated for 24 hours with the indicated amounts of ODNs. Read-out was performed by ELISA.

B cell activation with respect to ODN concentration. Human PBMCs were incubated with ODNs in the indicated amounts for 48 hours and stained for CD19, CD80, and CD86, then analyzed by flow cytometry using the MACSQuant® Analyzer. Cells were gated on live CD19+ cells.

TLR9-mediated NF-κB activation in a recombinant cell line. HEK293 cells were stably transfected with a TLR9-expression plasmid and an NF-κB-luciferase reporter plasmid. Cells were incubated for 16 hours with CpG ODN. TLR9-mediated NF-κB activity was detected by measuring luciferase activity by chemiluminescence. n-fold activation of luciferase expression was calculated in reference to medium background activity (no ODN added).

Proliferation of B cells with respect to ODN concentration. PBMC were stained with carboxyfluorescein diacetate succinimidyl ester, incubated with ODN and cultured for 6 days. Cells were stained with CD19 mAb and analyzed with the MACSQuant® Analyzer. Cells were gated on live CD19+ cells and % proliferating B cells were measured by decrease in CFSE content.

P-Class: activate both pDCs and B cells with higher efficiency than C-Class agonists. They can form multimeric structures.

IFN-α production in PBMCs with respect to ODN concentration. Human PBMCs were incubated for 24 hours with the indicated amounts of ODNs. Read-out was performed by ELISA.

IL-6 production in PBMCs with respect to ODN concentration. Human PBMCs were incubated for 24 hours with the indicated amounts of ODNs. Read-out was performed by ELISA.

TLR9-mediated NF-κB activation in a recombinant cell line. HEK293 cells were stably transfected with a TLR9-expression plasmid and an NF-κB-luciferase reporter plasmid. Cells were incubated for 16 hours with CpG ODN. TLR9-mediated NF-κB activity was detected by measuring luciferase activity by chemiluminescence. n-fold activation of luciferase expression was calculated in reference to medium background activity (no ODN added).

B cell activation with respect to ODN concentration. Human PBMCs were incubated with ODNs in the indicated amounts for 48 hours and stained for CD19, CD80, and CD86, then analyzed by flow cytometry using the MACSQuant® Analyzer. Cells were gated on live CD19+ cells.

Proliferation of B cells with respect to ODN concentration. PBMC were stained with carboxyfluorescein diacetate succinimidyl ester, incubated with ODN and cultured for 6 days. Cells were stained with CD19 mAb and analyzed with the MACSQuant® Analyzer. Cells were gated on live CD19+ cells and % proliferating B cells were measured by decrease in CFSE content.
Find products in TLR9 Agonists
25 products available


View "10" | "50" | "100" products/page
Showing 1-10 of 25
Product Order no. Price

ODN 1826

Components:
  • 200 µg lyophilized ODN
  • 1 mL 1x TE Buffer
 
130-100-274 $185.00

ODN 1826

Components:
  • 1 mg lyophilized ODN
  • 1 mL 1x TE Buffer
 
130-100-103 $625.00

ODN 1826 Control (ODN 2138)

Components:
  • 1 mg lyophilized ODN
  • 1 mL 1x TE Buffer
 
130-100-276 $615.00

ODN 1826 Control (ODN 2138)

Components:
  • 200 µg lyophilized ODN
  • 1 mL 1x TE Buffer
 
130-100-275 $185.00

ODN 1826 Ready-to-use

Content: 20×100 µg in 50 µL
 
130-109-373 $1,125.00

ODN 1826 Ready-to-use

Content: 5×100 µg in 50 µL
 
130-109-374 $405.00

ODN 1982

Components:
  • 1 mg lyophilized ODN
  • 1 mL 1x TE Buffer
 
130-100-277 $615.00

ODN 1982

Components:
  • 200 µg lyophilized ODN
  • 1 mL 1x TE Buffer
 
130-100-104 $185.00

ODN 2006

Components:
  • 1 mg lyophilized ODN
  • 1 mL 1x TE Buffer
 
130-100-105 $625.00

ODN 2006

Components:
  • 200 µg lyophilized ODN
  • 1 mL 1x TE Buffer
 
130-100-106 $185.00
View "10" | "50" | "100" products/page
Showing 1-10 of 25


You have inquired prices for more than 1000 products. Therefore, the PDF generation can take a while. You may wait until the PDF download is available, or you can request an e-mail which provides you with a download link as soon as the PDF is ready.
Please enter a valid email address
E-Mail:
 
Thank you for your request. We will send you a download link as soon as the pdf is ready.
 
The requested price list is being generated now. You may close this note and keep browsing through our shop. A new window will open once the document is ready for download.
 

Customer login

Go

Forgot password?
Register for account

0 Shopping cart

Contact

Miltenyi Biotec Inc.
Phone: +1 800 FOR MACS
Fax:+1 877 591 1060
macs@miltenyibiotec.com
Contact overview

Product finder

Antibody panel builder

Toolbox

Loading...

Get rewarded for the reagents you love

Get rewarded for reagents

Change country

Please select your country to continue